NEX Closes €1M to Bring Infection Intelligence to Hospitals

NEX Raises €1M to Bring Predictive Infection Intelligence to More Hospitals

July 25, 2026

NEX

NEX Closes €1M to Bring Infection Intelligence to Hospitals

NEX Raises €1M to Bring Predictive Infection Intelligence to More Hospitals

July 25, 2026

NEX

NEX Closes €1M to Bring Infection Intelligence to Hospitals

Infection Intelligence

Research Roots

Next Stages of Growth

NEX Closes €1M to Bring Infection Intelligence to Hospitals

NEX Health Intelligence has closed a €1 million pre-seed funding round to support the next stage of our growth and bring advanced Infection Intelligence to more hospitals.

The round was led by Brighteye Ventures, with participation from Adeline Arts & Science, AFI Ventures, Ventech’s impact fund, Momentous Ventures, the Conception X Angel Syndicate and a group of industry angels.

The investment marks an important step in taking NEX from research and early clinical validation towards wider hospital deployment.

Infection Intelligence

Healthcare-associated infections remain a major source of avoidable harm, longer hospital stays and operational pressure. The challenge is particularly urgent as antimicrobial resistance makes an increasing number of infections harder to treat.

Our infection intelligence is designed to help teams identify possible cases and clusters earlier, predict where infection risk may be emerging and understand how patients, wards and potential exposures may be connected.

This can save time during investigations, support earlier intervention, minimise exposure and help prevent secondary cases.

Research Roots

NEX was founded by Dr Ashleigh Myall during his PhD in Mathematics at Imperial College London, following his work supporting the NHS response to COVID-19. He later joined forces with Dr Chang Ho Yoon, bringing together expertise in mathematical modelling, artificial intelligence, clinical medicine and biomedical informatics.

Ash’s early work was supported through the Medical Research Foundation’s National PhD Training Programme in Antimicrobial Resistance Research. The underlying research has since been peer reviewed and published in The Lancet Digital Health.

“During my PhD at Imperial, I began building AI systems to predict where infections would spread next. That became the foundation for NEX.”
- Ashleigh Myall, CEO

By the time of the funding round, NEX was already working with NHS organisations and hospitals internationally.

Next Stages of Growth

The investment will allow NEX to:

Expand deployments across UK and international hospitals.
Complete critical UK regulatory and clinical safety work.
Generate real-world clinical and economic evidence from live hospital sites.
Continue developing the platform alongside Infection Prevention and Control teams.

We are grateful to our investors, clinical partners and the research and enterprise communities that have supported NEX from its earliest stages.

This round gives us the resources to take the next step carefully: deploying NEX in more hospitals, demonstrating its impact and working with clinical teams to make predictive Infection Intelligence part of everyday infection prevention.